Moleculin net loss narrows to $7.64 million in Q2 FY26; R&D expense rises to $5.45 million - MBRX News | RalliesMoleculin net loss narrows to $7.64 million in Q2 FY26; R&D expense rises to $5.45 million
M
MBRX• Cash flow
- Cash used in operating activities increased to USD 12.77 million in the first six months, while financing cash inflows fell to USD 11.23 million.
Clinical trial update
- MIRACLE trial enrollment reached 76 of 90 as of Aug. 6; Part A unblinding is expected between December 2026 and February 2027.
Q2 and first-half results
- Moleculin Biotech posted a net loss of USD 7.64 million in Q2 2026, narrowing from a USD 17.81 million loss a year earlier.
- Operating loss widened to USD 7.56 million as research and development expense rose 52.78% to USD 5.45 million.
- For the first half, net loss narrowed to USD 20.48 million from USD 23.71 million, helped by a USD 10.76 million warrant fair-value gain.
CTGO
•
